hotspot -WSS

hotspot

author：leisure time 2025-09-29 16:33:16 - browse：5666

Kevin Sayer, CEO of Dexcom Dexcom

For years, diabetes tech company Dexcom has been striving to get its continuous glucose monitors into the hands of type 2 diabetes patients. Last week at the American Diabetes Association’s conference, the company unveiled plans for software built entirely for these patients, including ones who don’t take insulin.

“We’ve been so focused on things that match the needs of somebody who manages diabetes every minute of every day, and insulin delivery,” Kevin Sayer, CEO of Dexcom, told STAT. “This new product is going to be designed to address the needs of somebody with diabetes who’s not doing that, who has type 2 diabetes and is on other drugs.”

Continuous glucose monitoring is already well-established among people with type 1 diabetes, who rely on constant insulin therapy. The technology, which helps patients noninvasively monitor their blood sugar levels and control their insulin pump in real time, has grown rapidly in use over the years, culminating in a $5 billion market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Christmas in the PICU brings some surprising joy

focus

WSS

Prime Medicine, Myeloid Therapeutics clash over genome

Medicare Advantage beneficiaries sue Humana over algorithm use

Lilly’s weekly insulin works as well as daily products, new studies show

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

WuXi Biologics execs register to lobby as Congress comes for the company

HHS suspends federal funding for EcoHealth Alliance

entertainment

hotspot

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

SEC charges former device maker CEO with $41 million fraud

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Cherokee Nation medical school graduates its first class

Medical leaders decry Supreme Court decision on affirmative action

Boston hospital trains restaurant workers on naloxone for overdoses

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

BioMarin wins approval for gene therapy to treat hemophilia A

Hottest summer in 2,000 years puts focus on extreme heat, health

Wikipedia

Prime Medicine, Myeloid Therapeutics clash over genome

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Lilly’s weekly insulin works as well as daily products, new studies show

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Boston hospital trains restaurant workers on naloxone for overdoses

What STAT readers think about the FDA and patient advocacy

entertainment

leisure time

focus

Wikipedia